260 related articles for article (PubMed ID: 34853079)
21. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Sharma S; Chung CY; Uryu S; Petrovic J; Cao J; Rickard A; Nady N; Greasley S; Johnson E; Brodsky O; Khan S; Wang H; Wang Z; Zhang Y; Tsaparikos K; Chen L; Mazurek A; Lapek J; Kung PP; Sutton S; Richardson PF; Greenwald EC; Yamazaki S; Jones R; Maegley KA; Bingham P; Lam H; Stupple AE; Kamal A; Chueh A; Cuzzupe A; Morrow BJ; Ren B; Carrasco-Pozo C; Tan CW; Bhuva DD; Allan E; Surgenor E; Vaillant F; Pehlivanoglu H; Falk H; Whittle JR; Newman J; Cursons J; Doherty JP; White KL; MacPherson L; Devlin M; Dennis ML; Hattarki MK; De Silva M; Camerino MA; Butler MS; Dolezal O; Pilling P; Foitzik R; Stupple PA; Lagiakos HR; Walker SR; Hediyeh-Zadeh S; Nuttall S; Spall SK; Charman SA; Connor T; Peat TS; Avery VM; Bozikis YE; Yang Y; Zhang M; Monahan BJ; Voss AK; Thomas T; Street IP; Dawson SJ; Dawson MA; Lindeman GJ; Davis MJ; Visvader JE; Paul TA
Cell Chem Biol; 2023 Oct; 30(10):1191-1210.e20. PubMed ID: 37557181
[TBL] [Abstract][Full Text] [Related]
22. FISH identifies a KAT6A/CREBBP fusion caused by a cryptic insertional t(8;16) in a case of spontaneously remitting congenital acute myeloid leukemia with a normal karyotype.
Barrett R; Morash B; Roback D; Pambrun C; Marfleet L; Ketterling RP; Harrison K; Berman JN
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28097792
[TBL] [Abstract][Full Text] [Related]
23. Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding.
Lv D; Jia F; Hou Y; Sang Y; Alvarez AA; Zhang W; Gao WQ; Hu B; Cheng SY; Ge J; Li Y; Feng H
Cancer Res; 2017 Nov; 77(22):6190-6201. PubMed ID: 29021135
[TBL] [Abstract][Full Text] [Related]
24. Transcription control by the ENL YEATS domain in acute leukaemia.
Erb MA; Scott TG; Li BE; Xie H; Paulk J; Seo HS; Souza A; Roberts JM; Dastjerdi S; Buckley DL; Sanjana NE; Shalem O; Nabet B; Zeid R; Offei-Addo NK; Dhe-Paganon S; Zhang F; Orkin SH; Winter GE; Bradner JE
Nature; 2017 Mar; 543(7644):270-274. PubMed ID: 28241139
[TBL] [Abstract][Full Text] [Related]
25. C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.
Marneth AE; Prange KHM; Al Hinai ASA; Bergevoet SM; Tesi N; Janssen-Megens EM; Kim B; Sharifi N; Yaspo ML; Kuster J; Sanders MA; Stoetman ECG; Knijnenburg J; Arentsen-Peters TCJM; Zwaan CM; Stunnenberg HG; van den Heuvel-Eibrink MM; Haferlach T; Fornerod M; Jansen JH; Valk PJM; van der Reijden BA; Martens JHA
Leukemia; 2018 Mar; 32(3):828-836. PubMed ID: 28871137
[TBL] [Abstract][Full Text] [Related]
26. Lysine acetyltransferase 6A maintains CD4
Fu JY; Huang SJ; Wang BL; Yin JH; Chen CY; Xu JB; Chen YL; Xu S; Dong T; Zhou HN; Ma XY; Pu YP; Li H; Yang XJ; Xie LS; Wang ZJ; Luo Q; Shao YX; Ye L; Zong ZR; Wei XD; Xiao WW; Niu ST; Liu YM; Xu HP; Yu CQ; Duan SZ; Zheng LY
Cell Metab; 2024 Mar; 36(3):557-574.e10. PubMed ID: 38237601
[TBL] [Abstract][Full Text] [Related]
27. HBO1 is required for the maintenance of leukaemia stem cells.
MacPherson L; Anokye J; Yeung MM; Lam EYN; Chan YC; Weng CF; Yeh P; Knezevic K; Butler MS; Hoegl A; Chan KL; Burr ML; Gearing LJ; Willson T; Liu J; Choi J; Yang Y; Bilardi RA; Falk H; Nguyen N; Stupple PA; Peat TS; Zhang M; de Silva M; Carrasco-Pozo C; Avery VM; Khoo PS; Dolezal O; Dennis ML; Nuttall S; Surjadi R; Newman J; Ren B; Leaver DJ; Sun Y; Baell JB; Dovey O; Vassiliou GS; Grebien F; Dawson SJ; Street IP; Monahan BJ; Burns CJ; Choudhary C; Blewitt ME; Voss AK; Thomas T; Dawson MA
Nature; 2020 Jan; 577(7789):266-270. PubMed ID: 31827282
[TBL] [Abstract][Full Text] [Related]
28. The Expression of Histone Acetyltransferase KAT6A in Non-small Cell Lung Cancer.
Partynska A; Piotrowska A; Pawelczyk K; Rzechonek A; Ratajczak-Wielgomas K; Podhorska-Okolow M; Dziegiel P
Anticancer Res; 2022 Dec; 42(12):5731-5741. PubMed ID: 36456139
[TBL] [Abstract][Full Text] [Related]
29. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
[TBL] [Abstract][Full Text] [Related]
31. Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia.
Bhreathnach Ú; Doherty D; Murphy K; Flynn CM; Langabeer SE
Leuk Res; 2022 May; 116():106823. PubMed ID: 35303627
[No Abstract] [Full Text] [Related]
32. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
33. Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy.
Boila LD; Sengupta A
Exp Hematol; 2020 Dec; 92():19-31. PubMed ID: 32950598
[TBL] [Abstract][Full Text] [Related]
34.
Singh M; Spendlove S; Wei A; Bondhus L; Nava A; de L Vitorino FN; Amano S; Lee J; Echeverria G; Gomez D; Garcia BA; Arboleda VA
bioRxiv; 2023 Aug; ():. PubMed ID: 37577627
[TBL] [Abstract][Full Text] [Related]
35. Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia.
Vitkevičienė A; Skliutė G; Žučenka A; Borutinskaitė V; Navakauskienė R
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681732
[TBL] [Abstract][Full Text] [Related]
36. Impaired cell fate through gain-of-function mutations in a chromatin reader.
Wan L; Chong S; Xuan F; Liang A; Cui X; Gates L; Carroll TS; Li Y; Feng L; Chen G; Wang SP; Ortiz MV; Daley SK; Wang X; Xuan H; Kentsis A; Muir TW; Roeder RG; Li H; Li W; Tjian R; Wen H; Allis CD
Nature; 2020 Jan; 577(7788):121-126. PubMed ID: 31853060
[TBL] [Abstract][Full Text] [Related]
37. Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer-Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression.
Chen Y; Ying Y; Ma W; Ma H; Shi L; Gao X; Jia M; Li M; Song X; Kong W; Chen W; Zheng X; Muluh TA; Wang X; Wang M; Shu XS
Cancer Res; 2024 Apr; 84(8):1237-1251. PubMed ID: 38241700
[TBL] [Abstract][Full Text] [Related]
38. Crosstalk between epigenetic readers regulates the MOZ/MORF HAT complexes.
Klein BJ; Lalonde ME; Côté J; Yang XJ; Kutateladze TG
Epigenetics; 2014 Feb; 9(2):186-93. PubMed ID: 24169304
[TBL] [Abstract][Full Text] [Related]
39. ENL, the gene fused with HRX in t(11;19) leukemias, encodes a nuclear protein with transcriptional activation potential in lymphoid and myeloid cells.
Rubnitz JE; Morrissey J; Savage PA; Cleary ML
Blood; 1994 Sep; 84(6):1747-52. PubMed ID: 8080983
[TBL] [Abstract][Full Text] [Related]
40. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
